Navigation Links
BioNeutral's Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
Date:8/19/2008

Ygiene(TM) Hospital Grade antimicrobial sets the new global standard to

eradicate (100% kill) in seconds the most difficult and lethal microorganisms commonly found in health care facilities, including MRSA and

C. difficile

NEWARK, N.J., Aug. 19 /PRNewswire/ -- BioNeutral announces successful testing of its Ygiene(TM) Hospital Grade antimicrobial against antibiotic-resistant microorganisms and spore forms of microorganisms which represent the major source of hospital acquired infections. In the US, Methicillan Resistant Staphylococcus Aureus (MRSA), Vancomycin-resistant Enterococci, Pan-resistant Klebsiellia pneumoniae and Clostridium difficile are but a few of the various lethal microorganisms present in hospital environments which contribute to over two-and-a-half million hospital acquired infections and one-hundred-thousand deaths annually. Using Ygiene(TM) Hospital Grade antimicrobial to routinely disinfect all areas in health care facilities can save many lives and billions of dollars annually in this global problem. Ygiene(TM) Hospital Grade antimicrobial has been found to completely eradicate these harmful microorganisms in seconds, and is still safe for the environment.

Dr. Philip Tierno, Principal Investigator and Head of Microbiology and Immunology at the Langone NYU Medical Center, has stated regarding Ygiene(TM) Hospital Grade antimicrobial: "No chemical formulation I have ever tested gives a quicker and more complete kill, has a broader spectrum of activity and is more 'green.'"

Dr. Andy Kielbania, Chief Scientist at BioNeutral, stated, "Despite the use of Lysol(R), Clorox(R) bleach, Oxivir(TM)Tb, Medica DC Germicidal Solution, Asepticare(R) TB+II, Germ Control 24 by Pure Biosciences and many other commercial disinfectants, the epidemic of infections continues in health care facilities. Most of these products are not sporicidal and either have no effect on the more difficult organisms,
'/>"/>

SOURCE BioNeutral Laboratories Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. U.S. Hospital Sales Opportunities Maximized Through Functional Optimization
2. Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide
3. St. Lukes Episcopal Hospital to Add CyberKnife System to Treatment Offerings
4. FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia
5. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
6. U.S. News Media Group Releases 19th Edition of Americas Best Hospitals
7. Isabel Healthcare Adds Hospitals in Wisconsin & Minnesota
8. Low-Power Ultra Wideband (UWB) Technology Best RFID Choice for Hospitals to Minimize Interference Threat
9. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
10. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
11. Number of Patients Treated with an Antibiotic for MRSA Within U.S. Acute Care Hospitals Increased 8 Percent from 2006 to 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... STOCKHOLM, September 4 Karolinska Development (publ),today ... has,concluded an extensive clinical study of its candidate drug, ... labor during childbirth.,The promising results of the Phase II ... Karolinska Development,s business strategy. , ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a ... that BioSpecifics, President, Tom Wegman, will present at the upcoming ... 10, 2009, at 12:05pm ET at the New York Palace ... A live webcast of the presentation can be accessed ...
... , , , , SAN ... the Company will present at the following investor conferences: , , ... 2:45 p.m. Eastern Time (ET) on September 9. , Thomas ... , The 2009 Morgan Stanley Global Healthcare Unplugged Conference in ...
Cached Biology Technology:Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 2Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 3Gen-Probe to Webcast Four Upcoming Investor Presentations 2
(Date:4/22/2014)... There are all sorts of signaling strategies in nature. ... tails; satin bowbirds build specialized stick structures, called bowers, ... European bitterling males show off bright nuptial coloration during ... to communicate with others. , ... profound fitness implications for individuals that are either signaling ...
(Date:4/22/2014)... must be aware of the broad patent landscape and ... a new paper from Rice University,s Baker Institute for ... the journal Regenerative Medicine , the paper is ... in the case Association for Molecular Pathology (AMP) v. ... court case and rulings garnered discussion in the public ...
(Date:4/22/2014)... have presented Beaumont Health System with prestigious, competitive ... both athletic and nonathletic injuries. , The ... $40,000 grant to fund stem cell-based research that ... a ruptured knee anterior cruciate ligament, or ACL. ... anterior cruciate ligament injury is the over-stretching or ...
Breaking Biology News(10 mins):Best practices in communication for the animal world 2Best practices in communication for the animal world 3New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3Beaumont awarded grants to study sports-related injury treatment, improve recovery 2
... Patients with symptomatic moderate asthma who were treated ... antibody, experienced significantly fewer disease exacerbations than individuals ... the first issue for October 2006 of the ... published by the American Thoracic Society. , Trevor ...
... harnessing of 'T-rays' - electromagnetic terahertz waves - which ... varied as biological cell abnormalities and explosives has been announced. ... in Spain have said they have found a way to ... Their findings are set out in a letter published in ...
... theories regarding consciousness, emotion and quality of life ... (ALS, also known as 'Lou Gerhig's disease') are ... interaction. ALS is a progressive disease that destroys ... latest issue of Psychophysiology. The article reviews the ...
Cached Biology News:Monoclonal antibody reduces exacerbations in asthmatics 2T-ray breakthrough could make detecting disease far easier 2Computer with brain connections changing quality of life of paralyzed 2
Glutamate Receptor 5/1a...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Dog polyclonal to Porcine Pancreatic Islets of Langerhans Cells ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Pig): Sonicated crude membrane fraction of porcine p...
Biology Products: